SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Lidak Pharm. [LDAKA]
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Volquardsen who wrote (375)8/15/1997 10:40:00 AM
From: MCorbley   of 1115
 
I am concerned that they released only a general summary and that the only numbers provided were the p values indicating the level of confidence and significance of the results. In this case, p=0.035 for the reduction in healing time. At first glance, this does not strike me as outstanding for such a large study. In the studies conducted in the Netherlands and Belgium which were published in 1996, which involved only 63 patients and 98 episodes, p=0.0003 for the difference in healing time between experimental and control associated with a first episode and p=0.02 for all 98 treatment episodes. (Lower p indicates greater confidence that the results are valid).

It may be that the big investors are waiting to see the real data. Perhaps someone with a more thorough knowledge of statistics could offer some insight?
M.C.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News